A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension

Alcon Research173 enrolled

Overview

The purpose of the study is to evaluate the safety and effectiveness of an investigational glaucoma therapy in patients with open-angle glaucoma or ocular hypertension.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

173

Conditions

Open-Angle Glaucoma Ocular Hypertension

Interventions

Travoprost 0.004%/Timolol 0.5% Ophthalmic SolutionDRUG

Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension

Latanoprost 0.005% Ophthalmic Solution (XALATAN)DRUG

Commercially marketed ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension

Timolol 0.5% Ophthalmic SolutionDRUG

Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * 18 years or older. * Diagnosis of open-angle glaucoma (with or without pseudoexfoliation or pigment dispersion component) or ocular hypertension. * Mean intraocular pressure (IOP) in at least one eye greater than 21 mmHg and less than or equal to 36 mmHg at screening visit. * Other protocol-defined inclusion criteria may apply. Exclusion Criteria: * Pregnant * History of chronic or recurrent severe inflammatory eye disease. * History of ocular infection or ocular inflammation within the past three months in either eye. * Other protocol-defined exclusion criteria may apply.

Outcomes

Primary Outcomes

Mean Intraocular Pressure (IOP) Change at 3 Months from Baseline

Time frame: 3 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.